These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

370 related articles for article (PubMed ID: 33284994)

  • 1. Inhibiting phosphoglycerate dehydrogenase counteracts chemotherapeutic efficacy against MYCN-amplified neuroblastoma.
    Arlt B; Zasada C; Baum K; Wuenschel J; Mastrobuoni G; Lodrini M; Astrahantseff K; Winkler A; Schulte JH; Finkler S; Forbes M; Hundsdoerfer P; Guergen D; Hoffmann J; Wolf J; Eggert A; Kempa S; Deubzer HE
    Int J Cancer; 2021 Mar; 148(5):1219-1232. PubMed ID: 33284994
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Venetoclax-based Rational Combinations are Effective in Models of
    Dalton KM; Krytska K; Lochmann TL; Sano R; Casey C; D'Aulerio A; Khan QA; Crowther GS; Coon C; Cai J; Jacob S; Kurupi R; Hu B; Dozmorov M; Greninger P; Souers AJ; Benes CH; Mossé YP; Faber AC
    Mol Cancer Ther; 2021 Aug; 20(8):1400-1411. PubMed ID: 34088831
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glycine decarboxylase is a transcriptional target of MYCN required for neuroblastoma cell proliferation and tumorigenicity.
    Alptekin A; Ye B; Yu Y; Poole CJ; van Riggelen J; Zha Y; Ding HF
    Oncogene; 2019 Dec; 38(50):7504-7520. PubMed ID: 31444411
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of Phosphoglycerate Dehydrogenase Attenuates Bleomycin-induced Pulmonary Fibrosis.
    Hamanaka RB; Nigdelioglu R; Meliton AY; Tian Y; Witt LJ; O'Leary E; Sun KA; Woods PS; Wu D; Ansbro B; Ard S; Rohde JM; Dulin NO; Guzy RD; Mutlu GM
    Am J Respir Cell Mol Biol; 2018 May; 58(5):585-593. PubMed ID: 29019702
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The synergy of BET inhibitors with aurora A kinase inhibitors in MYCN-amplified neuroblastoma is heightened with functional TP53.
    Yi JS; Sias-Garcia O; Nasholm N; Hu X; Iniguez AB; Hall MD; Davis M; Guha R; Moreno-Smith M; Barbieri E; Duong K; Koach J; Qi J; Bradner JE; Stegmaier K; Weiss WA; Gustafson WC
    Neoplasia; 2021 Jun; 23(6):624-633. PubMed ID: 34107377
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Limited Environmental Serine and Glycine Confer Brain Metastasis Sensitivity to PHGDH Inhibition.
    Ngo B; Kim E; Osorio-Vasquez V; Doll S; Bustraan S; Liang RJ; Luengo A; Davidson SM; Ali A; Ferraro GB; Fischer GM; Eskandari R; Kang DS; Ni J; Plasger A; Rajasekhar VK; Kastenhuber ER; Bacha S; Sriram RK; Stein BD; Bakhoum SF; Snuderl M; Cotzia P; Healey JH; Mainolfi N; Suri V; Friedman A; Manfredi M; Sabatini DM; Jones DR; Yu M; Zhao JJ; Jain RK; Keshari KR; Davies MA; Vander Heiden MG; Hernando E; Mann M; Cantley LC; Pacold ME
    Cancer Discov; 2020 Sep; 10(9):1352-1373. PubMed ID: 32571778
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Catastrophic ATP loss underlies a metabolic combination therapy tailored for
    Dalton KM; Lochmann TL; Floros KV; Calbert ML; Kurupi R; Stein GT; McClanaghan J; Murchie E; Egan RK; Greninger P; Dozmorov M; Ramamoorthy S; Puchalapalli M; Hu B; Shock L; Koblinski J; Glod J; Boikos SA; Benes CH; Faber AC
    Proc Natl Acad Sci U S A; 2021 Mar; 118(13):. PubMed ID: 33762304
    [No Abstract]   [Full Text] [Related]  

  • 8. Inhibiting PHGDH with NCT-503 reroutes glucose-derived carbons into the TCA cycle, independently of its on-target effect.
    Arlt B; Mastrobuoni G; Wuenschel J; Astrahantseff K; Eggert A; Kempa S; Deubzer HE
    J Enzyme Inhib Med Chem; 2021 Dec; 36(1):1282-1289. PubMed ID: 34192988
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of a small molecule inhibitor of 3-phosphoglycerate dehydrogenase to target serine biosynthesis in cancers.
    Mullarky E; Lucki NC; Beheshti Zavareh R; Anglin JL; Gomes AP; Nicolay BN; Wong JC; Christen S; Takahashi H; Singh PK; Blenis J; Warren JD; Fendt SM; Asara JM; DeNicola GM; Lyssiotis CA; Lairson LL; Cantley LC
    Proc Natl Acad Sci U S A; 2016 Feb; 113(7):1778-83. PubMed ID: 26831078
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serine-Glycine-One-Carbon Metabolism: The Hidden Achilles Heel of
    Garcia AR; Arsenian-Henriksson M
    Cancer Res; 2019 Aug; 79(15):3818-3819. PubMed ID: 31371280
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabolic Evaluation of MYCN-Amplified Neuroblastoma by 4-[
    Li C; Huang S; Guo J; Wang C; Huang Z; Huang R; Liu L; Liang S; Wang H
    Mol Imaging Biol; 2019 Dec; 21(6):1117-1126. PubMed ID: 30850970
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Repression of phosphoglycerate dehydrogenase sensitizes triple-negative breast cancer to doxorubicin.
    Zhang X; Bai W
    Cancer Chemother Pharmacol; 2016 Sep; 78(3):655-9. PubMed ID: 27473325
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thymidylate synthase inhibitor raltitrexed can induce high levels of DNA damage in MYCN-amplified neuroblastoma cells.
    Yamashita K; Kiyonari S; Tsubota S; Kishida S; Sakai R; Kadomatsu K
    Cancer Sci; 2020 Jul; 111(7):2431-2439. PubMed ID: 32415892
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A PHGDH inhibitor reveals coordination of serine synthesis and one-carbon unit fate.
    Pacold ME; Brimacombe KR; Chan SH; Rohde JM; Lewis CA; Swier LJ; Possemato R; Chen WW; Sullivan LB; Fiske BP; Cho S; Freinkman E; Birsoy K; Abu-Remaileh M; Shaul YD; Liu CM; Zhou M; Koh MJ; Chung H; Davidson SM; Luengo A; Wang AQ; Xu X; Yasgar A; Liu L; Rai G; Westover KD; Vander Heiden MG; Shen M; Gray NS; Boxer MB; Sabatini DM
    Nat Chem Biol; 2016 Jun; 12(6):452-8. PubMed ID: 27110680
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DNA Ligase 4 Contributes to Cell Proliferation against DNA-PK Inhibition in
    Ando K; Suenaga Y; Kamijo T
    Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37240360
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phosphoglycerate dehydrogenase promotes pancreatic cancer development by interacting with eIF4A1 and eIF4E.
    Ma X; Li B; Liu J; Fu Y; Luo Y
    J Exp Clin Cancer Res; 2019 Feb; 38(1):66. PubMed ID: 30744688
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cyclin-Dependent Kinase Inhibitor AT7519 as a Potential Drug for MYCN-Dependent Neuroblastoma.
    Dolman ME; Poon E; Ebus ME; den Hartog IJ; van Noesel CJ; Jamin Y; Hallsworth A; Robinson SP; Petrie K; Sparidans RW; Kok RJ; Versteeg R; Caron HN; Chesler L; Molenaar JJ
    Clin Cancer Res; 2015 Nov; 21(22):5100-9. PubMed ID: 26202950
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Role of D-3-Phosphoglycerate Dehydrogenase in Cancer.
    Zhao X; Fu J; Du J; Xu W
    Int J Biol Sci; 2020; 16(9):1495-1506. PubMed ID: 32226297
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Homoharringtonine as a PHGDH inhibitor: Unraveling metabolic dependencies and developing a potent therapeutic strategy for high-risk neuroblastoma.
    Hsieh CH; Huang CT; Cheng YS; Hsu CH; Hsu WM; Chung YH; Liu YL; Yang TS; Chien CY; Lee YH; Huang HC; Juan HF
    Biomed Pharmacother; 2023 Oct; 166():115429. PubMed ID: 37673018
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolic Reprogramming by MYCN Confers Dependence on the Serine-Glycine-One-Carbon Biosynthetic Pathway.
    Xia Y; Ye B; Ding J; Yu Y; Alptekin A; Thangaraju M; Prasad PD; Ding ZC; Park EJ; Choi JH; Gao B; Fiehn O; Yan C; Dong Z; Zha Y; Ding HF
    Cancer Res; 2019 Aug; 79(15):3837-3850. PubMed ID: 31088832
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 19.